> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# House FDA 2017 Spending Bill Passes Subcommittee
- URL: https://www.fdaweb.com/house-fda-2017-spending-bill-passes-subcommittee/
- Published: 2016-04-14T12:00:00.000Z
- Updated: 2026-09-14T20:54:51.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5135364

> A House appropriations subcommittee has approved a 2017 funding bill that would provide FDA $2.7 billion in discretionary spending, a $33 million (1%) increase over fiscal year 2016 spending levels. Including revenue from user fees, total 2017 funding is $4.78 billion – $97.4 million (2%) more than 2016\. Within this total, food safety activities are increased by $33.2 million, and medical product safety activities are increased by $9.4 million. The measure also provides $10 million in funding for the agency to combat Zika and Ebola outbreaks by helping to fund ongoing response activities, and to expedite the development and availability of medical products to fight the viruses.  
>  
>  
>  
> The bill also includes a policy provision directing the agency not to use any appropriated funds to finalize its controversial proposed rule to change generic drug labeling requirements unless certain conditions are met. For instance, the final rule should require FDA to approve in advance on a timely basis any change to a generic drug’s safety information. The provision also requires the agency to approve an identical change to the reference drug.  
>  
>  
>  
> During the subcommittee mark-up, Rep. **Rosa DeLauro** (D-CT) voiced opposition to the bill because of the generic drug labeling restrictions, among other issues. The measure passed on a voice vote, and it now heads to the full committee for consideration.  
>  
>  
>  
> The [Alliance for a Stronger FDA](http://www.fdaweb.com/download.php?file=Alliance%5FRelease%5FFY%5F17%5FHouse%5FSC%5FNumbers%5F4-14-16%5FFINAL2.doc) said the subcommittee bill “is heading in the right direction” in increasing FDA’s budget but is “in stark contrast to the steady investments over the past years in FDA’s critical public health work, including more than a $100 million increase in the prior fiscal year.” It said it is encouraged that the House proposal for FDA funding exceeds the Administration’s “meager request... Nonetheless, the House mark fails to acknowledge FDA’s rapidly expanding role in food and drug safety and innovative medical product development... We are concerned that the House subcommittee mark will require FDA to choose among competing public health priorities, which could put the health and safety of the American people at risk.”